The project took almost two years to complete, to a large extent, because of a particularly complex merger control issues, which were triggered by the transaction. This has led to one of the longest examinations of the notified concentration in Lithuanian history. During the merger examination the parties proposed remedies and commitments to Lithuanian Competition Council to divest a part of their business in Šiauliai and Kaunas. The commitments were successfully implemented by selling the divested business to an independent third party prior to the closing.
Following the transaction, INVL Baltic Sea Growth Fund remains the largest shareholder with 45% stake in InMedica through BSGF Sanus, another 40% owned by Latvia's largest private medical business group Repharm, and 15% by Litgaja.
INVL Baltic Sea Growth Fund was advised by the executive partner Marius Matonis, partners Aurimas Pauliukevičius, Dalia Tamašauskaitė-Žilienė, senior associate Julija Eymirlioglu, associates Paulius Dabulskis, Rimantė Varapnickė, Augustė Linauskaitė and Edvinas Einoris.